Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting...
Guardado en:
Autores principales: | Maria N. Chamurlieva, Yulia L. Korsakova, Stefka G. Radenska-Lopovok, Tatiana V. Korotaeva |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
State Scientific Center of Dermatovenereology and Cosmetology
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/91175d6222fa48c88b9edfe7b48b771d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis
por: Guerra Bautista G, et al.
Publicado: (2019) -
Revisiting the question of cutaneous vasculitis classification
por: Alexey V. Samtsov, et al.
Publicado: (2021) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler E, et al.
Publicado: (2021) -
Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report
por: Yeqing Xiao, et al.
Publicado: (2021) -
Management of rheumatoid arthritis during pregnancy: challenges and solutions
por: Krause ML, et al.
Publicado: (2016)